Search research articles
Contact Us
Filters
Showing results (21-30 of 135) with videos related to
Page
of 14
Sort By:
Polymers
|
August 28, 2021
Cellulose Nanocrystals Reinforced Zein/Catechin/β-Cyclodextrin Inclusion Complex Nanoparticles Nanocomposite Film for Active Food Packaging
Longwei Jiang, Yanlong Han, Xiangyi Meng, et al.
Primary Care Companion to the Journal of Clinical Psychiatry
|
January 29, 2011
Switching from oral donepezil to rivastigmine transdermal patch in Alzheimer's disease: 20-week extension phase results
Carl H Sadowsky, Alan Dengiz, Xiangyi Meng, et al.
Applied Biochemistry and Biotechnology
|
June 14, 2017
Improvement in Submergence Tolerance of Cherry Through Regulation of Carbohydrate Metabolism and Plant Growth by PsERF and PsCIPK
Lixia Sheng, Xiangyi Meng, Meng Wang, et al.
CNS Neuroscience & Therapeutics
|
April 2, 2014
Fingolimod therapy in early multiple sclerosis: an efficacy analysis of the TRANSFORMS and FREEDOMS studies by time since first symptom
Mark Agius, Xiangyi Meng, Peter Chin, et al.
Food Chemistry
|
July 1, 2021
Preparation and characterization of k-carrageenan/konjac glucomannan/TiO<sub>2</sub> nanocomposite film with efficient anti-fungal activity and its application in strawberry preservation
Nuo Duan, Qian Li, Xiangyi Meng, et al.
The Primary Care Companion for CNS Disorders
|
October 7, 2011
Predictors of sustained response to rivastigmine in patients with Alzheimer's disease: a retrospective analysis
Carl H Sadowsky, George T Grossberg, Monique Somogyi, et al.
Multiple Sclerosis and Related Disorders
|
July 27, 2016
Relapse rates in patients with multiple sclerosis treated with fingolimod: Subgroup analyses of pooled data from three phase 3 trials
Tobias Derfuss, Daniel Ontaneda, Jacqueline Nicholas, et al.
American Journal of Alzheimer'S Disease and Other Dementias
|
September 16, 2015
Cognitive Efficacy (SIB) of 13.3 Versus 4.6 mg/24 h Rivastigmine Patch in Severe Alzheimer's Disease
Richard S Isaacson, Steven Ferris, Drew M Velting, et al.
Current Medical Research and Opinion
|
November 26, 2009
A 25-week, open-label trial investigating rivastigmine transdermal patches with concomitant memantine in mild-to-moderate Alzheimer's disease: a post hoc analysis
Martin R Farlow, Gus Alva, Xiangyi Meng, et al.
Current Alzheimer Research
|
December 20, 2014
Evaluating high-dose rivastigmine patch in severe Alzheimer's disease: analyses with concomitant memantine usage as a factor
George T Grossberg, Martin R Farlow, Xiangyi Meng, et al.
Page
of 14
Search research articles
Search
Showing results (21-30 of 135) with videos related to
Sort By:
Page
of 14
Polymers
|
August 28, 2021
Cellulose Nanocrystals Reinforced Zein/Catechin/β-Cyclodextrin Inclusion Complex Nanoparticles Nanocomposite Film for Active Food Packaging
Longwei Jiang, Yanlong Han, Xiangyi Meng, et al.
Primary Care Companion to the Journal of Clinical Psychiatry
|
January 29, 2011
Switching from oral donepezil to rivastigmine transdermal patch in Alzheimer's disease: 20-week extension phase results
Carl H Sadowsky, Alan Dengiz, Xiangyi Meng, et al.
Applied Biochemistry and Biotechnology
|
June 14, 2017
Improvement in Submergence Tolerance of Cherry Through Regulation of Carbohydrate Metabolism and Plant Growth by PsERF and PsCIPK
Lixia Sheng, Xiangyi Meng, Meng Wang, et al.
CNS Neuroscience & Therapeutics
|
April 2, 2014
Fingolimod therapy in early multiple sclerosis: an efficacy analysis of the TRANSFORMS and FREEDOMS studies by time since first symptom
Mark Agius, Xiangyi Meng, Peter Chin, et al.
Food Chemistry
|
July 1, 2021
Preparation and characterization of k-carrageenan/konjac glucomannan/TiO<sub>2</sub> nanocomposite film with efficient anti-fungal activity and its application in strawberry preservation
Nuo Duan, Qian Li, Xiangyi Meng, et al.
The Primary Care Companion for CNS Disorders
|
October 7, 2011
Predictors of sustained response to rivastigmine in patients with Alzheimer's disease: a retrospective analysis
Carl H Sadowsky, George T Grossberg, Monique Somogyi, et al.
Multiple Sclerosis and Related Disorders
|
July 27, 2016
Relapse rates in patients with multiple sclerosis treated with fingolimod: Subgroup analyses of pooled data from three phase 3 trials
Tobias Derfuss, Daniel Ontaneda, Jacqueline Nicholas, et al.
American Journal of Alzheimer'S Disease and Other Dementias
|
September 16, 2015
Cognitive Efficacy (SIB) of 13.3 Versus 4.6 mg/24 h Rivastigmine Patch in Severe Alzheimer's Disease
Richard S Isaacson, Steven Ferris, Drew M Velting, et al.
Current Medical Research and Opinion
|
November 26, 2009
A 25-week, open-label trial investigating rivastigmine transdermal patches with concomitant memantine in mild-to-moderate Alzheimer's disease: a post hoc analysis
Martin R Farlow, Gus Alva, Xiangyi Meng, et al.
Current Alzheimer Research
|
December 20, 2014
Evaluating high-dose rivastigmine patch in severe Alzheimer's disease: analyses with concomitant memantine usage as a factor
George T Grossberg, Martin R Farlow, Xiangyi Meng, et al.
Page
of 14